Table 1 Clinical Trials for CAR-NK cells (2022–2024)
Antigen target | Disease target | Interventions | NCT Number | Sponsor | First Posted | Locations | Study Status | Data |
|---|---|---|---|---|---|---|---|---|
BCMA | MM|PCL | Human BCMA targeted CAR-NK cells injection | NCT06045091 | Hrain Biotechnology Co., Ltd | 2023 | China | RECRUITING | Not yet |
BCMA | MM | BCMA CAR-NK | NCT05652530 | Shenzhen Pregene Biopharma Co., Ltd | 2022 | China | RECRUITING | Not yet |
BCMA | MM | FT576 (Allogenic CAR NK cells with BCMA expression) | NCT05182073 | Fate Therapeutics | 2024 | USA | NOT_YET_RECRUITING | Not yet |
CD123 | R/R AML | CD123-CAR-NK cells | NCT05574608 | Affiliated Hospital to Academy of Military Medical Sciences | 2022 | China | RECRUITING | Not yet |
CD123 | R/R AML | JD123 injection | NCT06201247 | Peking University People’s Hospital | 2024 | China | RECRUITING | Not yet |
CD123 | AML|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Relapse Leukemia|Refractory Leukemia | CD123 targeted CAR-NK cells | NCT06006403 | Chongqing Precision Biotech Co., Ltd | 2023 | China | RECRUITING | Not yet |
CD19 | ALL | CAR-NK-CD19 Cells | NCT05563545 | Shanghai Simnova Biotechnology Co.,Ltd | 2022 | China | COMPLETED | Not yet |
CD19 | ALL|B-cell Lymphoma|CLL | allogenic CD19-CAR-NK cells | NCT05739227 | Xuzhou Medical University | 2023 | China | RECRUITING | Not yet |
CD19 | Diffuse Large B Cell Lymphoma | anti-CD19 CAR NK cells | NCT05673447 | Changhai Hospital | 2023 | China | RECRUITING | Not yet |
CD19 | B-Cell Lymphoblastic Leukemia/Lymphoma | Anti-CD19 UCAR-NK cells | NCT05654038 | 920th Hospital of Joint Logistics Support Force of People’s Liberation Army of China | 2022 | China | RECRUITING | Not yet |
CD19 | SLE | anti-CD19 CAR NK cells (KN5501) | NCT06010472 | Changhai Hospital | 2023 | China | RECRUITING | Not yet |
CD19 | B-cell Lymphoma|B-cell Leukemia | anti-CD19 UCAR-NK cells | NCT05570188 | Kunming Hope of Health Hospital | 2022 | China | WITHDRAWN | Not yet |
CD19 | B-cell NHL | anti-CD19 CAR-NK | NCT05472558 | Second Affiliated Hospital, School of Medicine, Zhejiang University | 2022 | China | RECRUITING | Not yet |
CD19 | ALL, CLL, NHL | CAR-NK-CD19 Cells | NCT05410041 | Beijing Boren Hospital | 2022 | China | RECRUITING | Not yet |
CD19 | R/R B-cell Hematologic Malignancies (Adult) | CD19-CAR-NK | NCT05645601 | Affiliated Hospital to Academy of Military Medical Sciences | 2022 | China | RECRUITING | Not yet |
CD19 | B-ALL(Repapse) | CD19 CAR-NK | NCT06631040 | Shahid Beheshti University of Medical Sciences | 2024 | Iran | NOT_YET_RECRUITING | Not yet |
CD19 | B-Cancer | NKX019 (allogeneic CAR-NK) | NCT05020678 | Nkarta, Inc | 2024 | USA | Recruiting | Not yet |
CD19 | NHL (R/R) | TAK-007 | NCT05020015 | Takeda | 2024 | USA | NOT_YET_RECRUITING | Not yet |
CD19 | NHL (R/R) | CD19CAR NK | NCT06206902 | Shanghai Simnova Biotechnology Co.,Ltd | 2024 | China | Recruiting | Not yet |
CD19 | Refractory B Cell-mediated Autoimmune Diseases | CNTY-101 (a CD19-targeted CAR iNK Cel | NCT06255028 | Century Therapeutics, Inc | 2024 | USA | Recruiting | Not yet |
CD19 | NHL (R/R) | CARCIK-CD19 | NCT05869279 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 2024 | Italy | Recruiting | Not yet |
CD19 (high affinity CD16, cyclophosphamide, fludarabine, Rituximab) | R/R NHL | A CD19t-haNK suspension,Cyclophosphamide, Fludarabine|DRUG: Rituximab | NCT05618925 | ImmunityBio, Inc | 2022 | USA | NOT_YET_RECRUITING | Not yet |
CD19 (IL-2 and lymphodepleting Chemotherapy) | R/R CD19-Positive B-Cell Malignancies|Indolent NHL|Aggressive NHL | CNTY-101, IL-2, Lymphodepleting Chemotherapy | NCT05336409 | Century Therapeutics, Inc | 2022 | USA | RECRUITING | Not yet |
CD19/CD70 | B-cell NHL | CB dualCAR-NK19/70 | NCT05667155 | Second Affiliated Hospital, School of Medicine, Zhejiang University | 2022 | China | RECRUITING | Not yet |
CD19/CD70 | R/R B-cell NHL | dualCAR-NK19/70 cell | NCT05842707 | Aibin Liang, MD, Ph.D | 2023 | China | RECRUITING | Not yet |
CD33/CLL1 (Cyclophosphamide/Fludarabine/Ctarabine | AML, Adult|Minimal Residual Disease | CD33/CLL1 dual CAR-NK cell|DRUG: Cyclophosphamid|DRUG: Fludarabine|DRUG: Cytarabine|DRUG: CD33 CAR-NK cell|DRUG: super NK cell | NCT05987696 | Institute of Hematology & Blood Diseases Hospital, China | 2023 | China | NOT_YET_RECRUITING | Not yet |
CD5 (IL-15 transduction,Fludarabine, Cyclophosphamide)) | Hematological Malignancy | Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells | NCT05110742 | M.D. Anderson Cancer Center | 2021 | USA | NOT_YET_RECRUITING | Not yet |
CD70 (IL-15 transduction, Fludarabine, Cyclophosphamide) | Advanced Renal Cell Carcinoma|Advanced Mesothelioma|Advanced Osteosarcoma | CAR.70/IL15-transduced CB-derived NK cells, Fludarabine phosphate, Cyclophosphamide | NCT05703854 | M.D. Anderson Cancer Center | 2023 | USA | RECRUITING | Not yet |
CD70 (IL-15 transduction, Fludarabine) | B-Cell Lymphoma|MDS|AML | CyclophosphamidE, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate | NCT05092451 | M.D. Anderson Cancer Center | 2021 | USA | RECRUITING | Not yet |
Claudin6, GPC3, Mesothelin, or AXL | Stage IV Ovarian Cancer|Testis Cancer, Refractory|Endometrial Cancer Recurrent|CAR NK | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells | NCT05410717 | Second Affiliated Hospital of Guangzhou Medical University | 2022 | China | RECRUITING | Not yet |
CLL1 | AML, Adult | CLL1 CAR-NK cell injection | NCT06027853 | Zhejiang University | 2023 | China | RECRUITING | Not yet |
CLL1 or CD33 | AML (Adult) | iPSC -CAR-NK | NCT06367673 | The first affiliated hospital, Zhejiang University | 2024 | China | Recruiting | Not yet |
DLL3 | SCLC, Extensive Stage | DLL3-CAR-NK cells | NCT05507593 | Tianjin Medical University Cancer Institute and Hospital | 2022 | China | RECRUITING | Not yet |
NKG2D ligands | Ovarian Cancer | NKG2D CAR-NK | NCT05776355 | Hangzhou Cheetah Cell Therapeutics Co., Ltd | 2023 | China | RECRUITING | Not yet |
NKG2D ligands | AML | NKG2D CAR-NK | NCT05734898 | Zhejiang University | 2023 | China | RECRUITING | Not yet |
NKG2D ligands | AML, MDS | NKX101-CAR NK | NCT04623944 | Nkarta, Inc | 2024 | USA | NOT_YET_RECRUITING | Not yet |
SZ003 | HCC (Advanced) | A SZ003 CAR-NK | NCT05845502 | Shantou University Medical College | 2023 | Â | NOT_YET_RECRUITING | Not yet |
SZ011 | Ovarian Epithelial Carcinoma | SZ011 CAR-NK | NCT05856643 | Shantou University Medical College | 2023 | Â | NOT_YET_RECRUITING | Not yet |
SZ011 | Advanced Triple Negative Breast Cancer | SZ011 CAR-NK | NCT05686720 | First Affiliated Hospital of Shantou University Medical College | 2023 | China | NOT_YET_RECRUITING | Not yet |
TROP2 | Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | TROP2-CAR-NK | NCT06358430 | M.D. Anderson Cancer Center | 2024 | USA | NOT_YET_RECRUITING | Not yet |
TROP2 (Cyclophosphamide and Fludarabine) | Pancreatic Cancer|Ovarian Cancer|Adenocarcinoma | TROP2-CAR-NK|DRUG: Cyclophosphamide|DRUG: Fludarabine | NCT05922930 | M.D. Anderson Cancer Center | 2023 | USA | RECRUITING | Not yet |
TROP2 (Cyclophosphamide and Fludarabine) | Solid Tumors | Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate, Cyclophosphamide | NCT06066424 | M.D. Anderson Cancer Center | 2023 | USA | RECRUITING | Not yet |